Company: SMNR
Filing Date: 2025-08-15
Form Type: 10-Q
Source: 0001213900-25-077047
Chunk: 2

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-08-15
Form: 10-Q
Item: Part I, Item 1
Chunk 2
---
 $448,912  
    $(579,725) 
    $713,242 

    Basic and diluted weighted average redeemable ordinary shares outstanding 
     121,552  
     4,537,829  
     433,193  
     4,537,829 
  
    Basic and diluted net income per redeemable ordinary shares 
    $0.02  
    $0.13  
    $0.09  
    $0.23 

    Basic and diluted weighted average non-redeemable ordinary shares outstanding 
     2,572,500  
     2,572,500  
     2,572,500  
     2,572,500.00 
  
    Basic and diluted net loss per non-redeemable ordinary share 
    $(0.15) 
    $(0.05) 
    $(0.24) 
    $(0.12)

The accompanying notes are an integral
part of these unaudited condensed financial statements.

2

DENALI CAPITAL ACQUISITION CORP.

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS’
DEFICIT

(Unaudited)

    For the Three and Six Months Ended June 30, 2025 

    Class A Ordinary Shares  
    Class B Ordinary Shares  
    Accumulated  
    Shareholders’ 

    Shares  
    Amount  
    Shares  
    Amount  
    Deficit  
    Equity Deficit 
  
    Balance as of December 31, 2024 (Audited) 
     510,000  
    $51  
     2,062,500  
     206  
    $(10,417,973) 
     (10,417,716)
  
    Net loss 
     -  
     -  
     -  
     -  
     (194,603) 
     (194,603)
  
    Subsequent measurement of ordinary shares subject to possible redemption (interest earned on trust account and extension deposit) 
     -  
     -  
     -  
     -  
     (124,162) 
     (124,162)
  
    Balance as of March 31, 2025 (Unaudited) 
     510,000  
     51